Literature DB >> 31008816

Adenosine A3 receptor activation inhibits pronociceptive N-type Ca2+ currents and cell excitability in dorsal root ganglion neurons.

Elisabetta Coppi1, Federica Cherchi1, Irene Fusco1, Paola Failli1, Alessia Vona1, Ilaria Dettori1, Lisa Gaviano1, Elena Lucarini1, Kenneth A Jacobson2, Dilip K Tosh2, Daniela Salvemini3, Carla Ghelardini1, Felicita Pedata1, Lorenzo Di Cesare Mannelli1, Anna Maria Pugliese1.   

Abstract

Recently, studies have focused on the antihyperalgesic activity of the A3 adenosine receptor (A3AR) in several chronic pain models, but the cellular and molecular basis of this effect is still unknown. Here, we investigated the expression and functional effects of A3AR on the excitability of small- to medium-sized, capsaicin-sensitive, dorsal root ganglion (DRG) neurons isolated from 3- to 4-week-old rats. Real-time quantitative polymerase chain reaction experiments and immunofluorescence analysis revealed A3AR expression in DRG neurons. Patch-clamp experiments demonstrated that 2 distinct A3AR agonists, Cl-IB-MECA and the highly selective MRS5980, inhibited Ca-activated K (KCa) currents evoked by a voltage-ramp protocol. This effect was dependent on a reduction in Ca influx via N-type voltage-dependent Ca channels, as Cl-IB-MECA-induced inhibition was sensitive to the N-type blocker PD173212 but not to the L-type blocker, lacidipine. The endogenous agonist adenosine also reduced N-type Ca currents, and its effect was inhibited by 56% in the presence of A3AR antagonist MRS1523, demonstrating that the majority of adenosine's effect is mediated by this receptor subtype. Current-clamp recordings demonstrated that neuronal firing of rat DRG neurons was also significantly reduced by A3AR activation in a MRS1523-sensitive but PD173212-insensitive manner. Intracellular Ca measurements confirmed the inhibitory role of A3AR on DRG neuronal firing. We conclude that pain-relieving effects observed on A3AR activation could be mediated through N-type Ca channel block and action potential inhibition as independent mechanisms in isolated rat DRG neurons. These findings support A3AR-based therapy as a viable approach to alleviate pain in different pathologies.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31008816      PMCID: PMC6669900          DOI: 10.1097/j.pain.0000000000001488

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   7.926


  57 in total

1.  Selectivity of different calcium antagonists on T- and L-type calcium currents in guinea-pig ventricular myocytes.

Authors:  Petra De Paoli; Elisabetta Cerbai; Bernd Koidl; Michael Kirchengast; Laura Sartiani; Alessandro Mugelli
Journal:  Pharmacol Res       Date:  2002-12       Impact factor: 7.658

Review 2.  Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.

Authors:  S Vink; P F Alewood
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 3.  Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain.

Authors:  Mark J Field; Zheng Li; Jacob B Schwarz
Journal:  J Med Chem       Date:  2007-05-10       Impact factor: 7.446

4.  Adenosine agonists reduce voltage-dependent calcium conductance of mouse sensory neurones in cell culture.

Authors:  R L MacDonald; J H Skerritt; M A Werz
Journal:  J Physiol       Date:  1986-01       Impact factor: 5.182

5.  Antinociception of intrathecal adenosine receptor subtype agonists in rat formalin test.

Authors:  Myung Ha Yoon; Hong Beom Bae; Jeong Il Choi
Journal:  Anesth Analg       Date:  2005-11       Impact factor: 5.108

6.  Pain as a global public health priority.

Authors:  Daniel S Goldberg; Summer J McGee
Journal:  BMC Public Health       Date:  2011-10-06       Impact factor: 3.295

Review 7.  Intrathecal ziconotide for refractory chronic pain.

Authors:  Shalini S Lynch; Christine M Cheng; Jennie L Yee
Journal:  Ann Pharmacother       Date:  2006-07-18       Impact factor: 3.154

8.  Metabolic mapping of A3 adenosine receptor agonist MRS5980.

Authors:  Zhong-Ze Fang; Dilip K Tosh; Naoki Tanaka; Haina Wang; Kristopher W Krausz; Robert O'Connor; Kenneth A Jacobson; Frank J Gonzalez
Journal:  Biochem Pharmacol       Date:  2015-07-23       Impact factor: 5.858

9.  Characterization of voltage-and Ca2+-activated K+ channels in rat dorsal root ganglion neurons.

Authors:  Wei Li; Shang-Bang Gao; Cai-Xia Lv; Ying Wu; Zhao-Hua Guo; Jiu-Ping Ding; Tao Xu
Journal:  J Cell Physiol       Date:  2007-08       Impact factor: 6.384

10.  Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms.

Authors:  Carrie Wahlman; Timothy M Doyle; Joshua W Little; Livio Luongo; Kali Janes; Zhoumou Chen; Emanuela Esposito; Dilip K Tosh; Salvatore Cuzzocrea; Kenneth A Jacobson; Daniela Salvemini
Journal:  Pain       Date:  2018-06       Impact factor: 7.926

View more
  20 in total

1.  Characterization of Dual-Acting A3 Adenosine Receptor Positive Allosteric Modulators That Preferentially Enhance Adenosine-Induced Gαi3 and GαoA Isoprotein Activation.

Authors:  Courtney L Fisher; Lucas B Fallot; Tina C Wan; Robert F Keyes; R Rama Suresh; Amy C Rothwell; Zhan-Guo Gao; John D McCorvy; Brian C Smith; Kenneth A Jacobson; John A Auchampach
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-15

2.  Adenosine A3 agonists reverse neuropathic pain via T cell-mediated production of IL-10.

Authors:  Mariaconcetta Durante; Silvia Squillace; Filomena Lauro; Luigino Antonio Giancotti; Elisabetta Coppi; Federica Cherchi; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Grant Kolar; Carrie Wahlman; Adeleye Opejin; Cuiying Xiao; Marc L Reitman; Dilip K Tosh; Daniel Hawiger; Kenneth A Jacobson; Daniela Salvemini
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 14.808

Review 3.  Purinergic Signaling: Impact of GPCR Structures on Rational Drug Design.

Authors:  Veronica Salmaso; Kenneth A Jacobson
Journal:  ChemMedChem       Date:  2020-09-18       Impact factor: 3.540

4.  The Use of the Selective Imidazoline I1 Receptor Agonist Carbophenyline as a Strategy for Neuropathic Pain Relief: Preclinical Evaluation in a Mouse Model of Oxaliplatin-Induced Neurotoxicity.

Authors:  Laura Micheli; Lorenzo Di Cesare Mannelli; Fabio Del Bello; Mario Giannella; Alessandro Piergentili; Wilma Quaglia; Donatello Carrino; Alessandra Pacini; Carla Ghelardini
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

5.  The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis.

Authors:  Luca Antonioli; Elena Lucarini; Catia Lambertucci; Matteo Fornai; Carolina Pellegrini; Laura Benvenuti; Lorenzo Di Cesare Mannelli; Andrea Spinaci; Gabriella Marucci; Corrado Blandizzi; Carla Ghelardini; Rosaria Volpini; Diego Dal Ben
Journal:  Cells       Date:  2020-06-21       Impact factor: 6.600

6.  Transient receptor potential ankyrin 1 contributes to somatic pain hypersensitivity in experimental colitis.

Authors:  Piyush Jain; Serena Materazzi; Francesco De Logu; Duccio Rossi Degl'Innocenti; Camilla Fusi; Simone Li Puma; Ilaria M Marone; Elisabetta Coppi; Peter Holzer; Pierangelo Geppetti; Romina Nassini
Journal:  Sci Rep       Date:  2020-05-25       Impact factor: 4.379

Review 7.  Studying human nociceptors: from fundamentals to clinic.

Authors:  Steven J Middleton; Allison M Barry; Maddalena Comini; Yan Li; Pradipta R Ray; Stephanie Shiers; Andreas C Themistocleous; Megan L Uhelski; Xun Yang; Patrick M Dougherty; Theodore J Price; David L Bennett
Journal:  Brain       Date:  2021-06-22       Impact factor: 15.255

8.  Acute visceral pain relief mediated by A3AR agonists in rats: involvement of N-type voltage-gated calcium channels.

Authors:  Elena Lucarini; Elisabetta Coppi; Laura Micheli; Carmen Parisio; Alessia Vona; Federica Cherchi; Anna M Pugliese; Felicita Pedata; Paola Failli; Seph Palomino; Jared Wahl; Tally M Largent-Milnes; Todd W Vanderah; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini; Carla Ghelardini; Lorenzo Di Cesare Mannelli
Journal:  Pain       Date:  2020-09-01       Impact factor: 7.926

9.  Treatment of chronic neuropathic pain: purine receptor modulation.

Authors:  Kenneth A Jacobson; Luigino Antonio Giancotti; Filomena Lauro; Fatma Mufti; Daniela Salvemini
Journal:  Pain       Date:  2020-07       Impact factor: 7.926

10.  Inflammatory Bowel Diseases: It's Time for the Adenosine System.

Authors:  Luca Antonioli; Matteo Fornai; Carolina Pellegrini; Lorenzo Bertani; Zoltan H Nemeth; Corrado Blandizzi
Journal:  Front Immunol       Date:  2020-07-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.